NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
12 trialsNCT05267626 2026-02-18
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT03169738 2025-02-21
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03050554 2024-08-09
SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
University of California, San Diego
Phase 1/2 Terminated
NCT03386929 2023-12-18
SPRING
Worldwide Innovative Network Association
Phase 1/2 Terminated
NCT03409458 2023-11-18
PAVE-1
Promontory Therapeutics Inc.
Phase 1/2 Completed
NCT03399552 2023-10-23
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03330405 2023-10-13
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT03317496 2023-08-29
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
Pfizer
Phase 1/2 Terminated
NCT03268057 2022-05-02
CLASSICAL-Lung
Vaccinex Inc.
Phase 1/2 Completed
NCT02349633 2021-06-10
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
Pfizer
Phase 1/2 Terminated